New Mexico Patent of the Month – April 2024
The landscape of antibody development is evolving rapidly, with researchers continuously striving to enhance the efficacy and safety of therapeutic antibodies. One notable advancement in this field comes from Specifica, Inc., who has pioneered a groundbreaking approach to antibody library construction.
Specifica is a rapidly growing antibody engineering company focused on building exceptional antibody libraries. The company has used next-generation sequencing to build their newly patented Generation 3 Antibody Library discovery platform.
Traditionally, antibody libraries have been generated through methods such as humanization of murine monoclonal antibodies or in vitro selection from synthetic libraries. However, these approaches often face limitations in yield, specificity, and diversity. Specifica’s innovation lies in the creation of antibody libraries that harness the power of naturally-occurring antibodies, offering a novel solution to these challenges.
Their approach involves the assembly of antibody libraries comprising diversified heavy and/or light chain variable domains, sourced from naturally-occurring antibodies such as those found in humans or camelids. By leveraging the inherent diversity and functionality of natural antibodies, Specifica’s libraries boast a high number of functional members and reflect the rich repertoire of the immune system.
One key feature of Specifica’s antibody libraries is the exclusion of members carrying liabilities that may affect antibody properties, such as glycosylation sites or motifs promoting aggregation. This selective exclusion enhances the proportion of library members with desired properties, such as high yield, stability, and reduced aggregation capacity.
Specifica’s method allows for the customization of antibody libraries to meet specific therapeutic needs. Researchers can tailor the libraries by selecting antibody frameworks and optimizing the composition of complementarity determining regions (CDRs), ensuring the generation of antibodies with desired characteristics.
The implications of Specifica’s invention are far-reaching. Their antibody libraries hold promise for accelerating drug discovery and development, facilitating the creation of safer and more effective therapeutic antibodies. Moreover, by harnessing the natural diversity of the immune system, Specifica’s approach represents a paradigm shift in antibody engineering, paving the way for the next generation of biologics.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
